Table 3. Patients with a discordant KRAS status between primary tumour and liver metastasis. Multiple blocks of primary tumour tissue and lymph node metastases were tested when available.
KRAS status primary tumour | KRAS status 2nd tumour | KRAS status lymph node metastasis | KRAS status liver metastasis | |
---|---|---|---|---|
1 | Gly12Ala | — | LN 1: Gly12Ala | WT |
LN 2: Gly12Ala | ||||
LN 3: Gly12Ala | ||||
2 | Gly12Asp | — | — | WT |
Gly12Asp | ||||
WT | ||||
3 | Gly12Cys | — | — | WT |
4 | Gly12Asp | — | LN 1: Gly12Asp | WT |
Gly12Asp | LN 2: Gly12Asp | |||
Gly12Asp | LN 3: Gly12Asp | |||
Gly12Asp | LN 4: Gly12Asp | |||
LN 5: WT | ||||
5 | Gly12Ser | — | — | WT |
6 | WT | — | — | Gly12Cys |
7 | Gly12Asp | — | LN 1: WT | Gly12Ala |
LN 2: WT | ||||
LN 3: WT | ||||
8 | Gly13Asp | Gly13Asp | LN 1: Gly13Asp | Gly12Ser |
9 | Gly12Ser | — | — | Gly12Ala |
10 | Gly12Cys | — | LN 1: Gly12Asp | Gly12Asp |
Gly12Asp | LN 2: Gly12Asp | |||
LN 3: Gly12Asp | ||||
LN 4: Gly12Asp | ||||
LN 5: Gly12Asp | ||||
LN 6: WT | ||||
11 | Gly12Asp/Gly12Val | — | LN 1: Gly12Val | Gly12Asp |
LN 2: Gly12Val | ||||
LN 3: Gly12Val | ||||
LN 4: Gly12Asp | ||||
LN 5: Gly12Asp | ||||
LN 6: Gly12Asp | ||||
LN 7: Gly12Asp |
Abbreviation: WT=wild type.